Christine Posted October 22, 2007 Share Posted October 22, 2007 ZURICH, Oct 22 (Reuters) - Swiss drugmaker Roche said on Monday its lung cancer drug Tarceva received regulatory approval in Japan. "Roche, Chugai and OSI Pharmaceuticals, Inc. announced today that Tarceva (erlotinib) has been approved in Japan for the treatment of patients with nonresectable, recurrent and advanced non-small cell lung cancer (NSCLC) which is aggravated following chemotherapy," Roche said. Reporting by Sven Egenter Email: sven-markus.egenter@reuters.com Quote Link to comment Share on other sites More sharing options...
Recommended Posts
Join the conversation
You can post now and register later. If you have an account, sign in now to post with your account.